Evidence map›Paper›PMID 34275483›Full record

SynthesisSystematic reviews2021

Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis.

John E Feliciano-Alfonso, Juliana Muñoz-Ortiz, María Alejandra Marín-Noriega, Andrés Vargas-Villanueva, Laura Triviño-Blanco, Natalia Carvajal-Saiz, Alejandra de-la-Torre

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Systematic reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Frontiers in cellular and infection microbiology · 2022
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

John E Feliciano-AlfonsoDepartamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia.
Juliana Muñoz-OrtizNeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.
María Alejandra Marín-NoriegaNeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.
Andrés Vargas-VillanuevaNeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.
Laura Triviño-BlancoNeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.
Natalia Carvajal-SaizNeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.
Alejandra de-la-TorreNeURos Research Group, Escuela de Medicina Y Ciencias de La Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia. alejadelatorre@yahoo.com.
Universidad del Rosario · COInstituto Barraquer de América · COUniversidad Nacional de Colombia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOcular toxoplasmosis (OT) is the most common cause of posterior uveitis, which leads to visual impairment in a large proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual loss by controlling infection and inflammation. However, there remains disagreement regarding optimal antibiotic therapy for OT. Therefore, this systematic review and meta-analysis were performed to determine the effects and safety of existing antibiotic treatment regimens for OT.

methodsMEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, LILACS, WHO International Clinical Trials Registry Platform portal, ClinicalTrials.gov, and Gray Literature in Europe ("OpenGrey") were searched for relevant studies; manual searches of reference lists were performed for studies identified by other methods. All published and unpublished randomized controlled trials that compared antibiotic schemes known to be effective in OT at any dosage, duration, and administration route were included. Studies comparing antibiotics with placebo were excluded. This review followed standard methodological procedures recommended by the Cochrane group.

resultsTen studies were included in the narrative summary, of which four were included for quantitative synthesis (meta-analysis). Interventions were organized into three groups: intravitreal clindamycin versus pyrimethamine + sulfadiazine, trimethoprim + sulfamethoxazole versus other antibiotics, and other interventions. The first comparison favored intravitreal clindamycin (Mean difference (MD) = 0.10 logMAR; 95% confidence interval = 0.01 to 0.22). However, this finding lacks clinical relevance. Other outcomes showed no statistically significant differences between the treatment groups. In general, the risk of performance bias was high in evaluated studies, and the quality of the evidence found was low to very low.

conclusionsNo antibiotic scheme was superior to others, and the selection of a treatment regimen depends on multiple factors; therefore, treatment should be chosen based on safety, sulfa allergies, and availability.

Indexed as

Anti-Bacterial AgentsToxoplasmosis, OcularClindamycinEuropeHumansAnti-Bacterial AgentsClindamycinAnti-bacterial agentsocularTherapeuticsToxoplasma gondiiToxoplasmosisUveitis

Identifiers

PMID34275483
PMCPMC8287816
OpenAlexW3186913945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.